Skip to main content

In the News


July

ChromaDex Initiates Human Clinical Trial of NIAGEN™, Based On Licensed Cornell Technology

ChromaDex Corp., a natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announce the initiation of the first human clinical study for its patented ingredient NIAGEN™, a commercially available form of nicotinamide riboside (NR), based on licensed Cornell technology.

Researchers from WCMC Reprogram Cells for Treating Blood Disorders

Weill Cornell Medical College researchers have directly reprogrammed vascular cells into long-lasting blood cells that resemble bone marrow stem cells capable of forming the various components of blood necessary for life and could eventually offer millions of patients with blood disorders curative therapies derived from their own cells.

Cornell Startup, MetaStat, Inc., Closes $5.7 Million Equity Financing

MetaStat, a life sciences company focused on understanding and treating systemic metastasis, announced that it has entered into a securities purchase agreement in a private placement totaling $5.7 million, which will enable the company to accelerate the development and commercialization of its cancer diagnostic platform.

Cornell Startup, GeneWeave Biosciences Inc., Attracts $12 Million to Provide Diagnostic Solutions for Multi-Drug-Resistant Organisms

GeneWeave, an in vitro diagnostics company that advances clinical microbiology with diagnostic solutions to prevent drug-resistant infections, announced the completion of its $12 million Series B financing to support clinical studies and commercialization of the company’s sample-in/susceptibility-out platform technology.


June

Cornell Startup, ZetrOZ, Inc., Raises $2 Million for Sam®, Its Wearable Ultrasound Device

ZetrOZ, a medical device company developing ultrasound therapies, has raised more than $2 million for Sam®, an FDA-cleared, iPod-sized, wearable device designed to relieve pain and improve circulation.

GenDx to Offer a Version of NGSgo® Reagent Line for Cornell Startup, Pacific Biosciences of California, Inc.'s Gene Sequencing System

GenDX, a Dutch molecular diagnostics company that develops In Vitro Diagnostic (IVD) tests and services, and Pacific Biosciences, provider of the PacBio® RS II DNA sequencing system, announced a co-marketing agreement to offer a new reagent kit for full-length Human Leukocyte Antigen (HLA) gene sequencing.  

Weill Cornell Researchers Have Discovered A Drug Therapy That May Prevent Tongue Cancer

A drug combination discovered at Weill Cornell Medical College shows promise in the preventative treatment of individuals at risk for developing tongue cancer.

Ithaca Firm and Cornell Team Up in 3D Printing Enterprise in First Wave of StartUP NY

Incodema3D, an offshoot of a rapid prototyping firm looking to expand into additive manufacturing to create precision metal and plastic components, will be the first StartUp NY business in Tompkins County.

VERSABALL® From Cornell Startup, Empire Robotics, Inc., Wins First Prize at Service Robotics Awards

VERSABALL®, a flexible method of gripping and moving objects from Empire Robotics, won first place at the Service Robotics Awards Ceremony held at AUTOMATICA 2014 in Munich, Germany.

Cornell Startup, Metabolon, Inc., Announces Quantose IR™ Prediabetes Test Is Now Available In Mexico

Metabolon, a commercial-stage metabolomics company in the field of biochemical pathway analysis for biomarker discovery and development of innovative, cost-effective diagnostic tests, announced that its Quantose IR™ prediabetes test is now available to physicians in Mexico through its commercial partner PATIA Biopharma.  

Cornell Startup, MetaStat, Inc., Announces Results of MetaSite Breast Test Study

MetaStat, a life science company that develops diagnostic products and novel therapeutics for the early and reliable prediction and treatment of systemic metastasis, announced the publication of results from a study of its MetaSite Breast test that validate the test’s ability to show a strong and statistically significant association with the risk of metastasis for the most common type of breast cancer. 

For archived news items, click here.